The dietary supplement Cyplexinol® alleviates joint pain in men and women.

Jacquelyn Pence, Michelle Stockton, Richard J Bloomer
{"title":"The dietary supplement Cyplexinol<sup>®</sup> alleviates joint pain in men and women.","authors":"Jacquelyn Pence,&nbsp;Michelle Stockton,&nbsp;Richard J Bloomer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.</p><p><strong>Methods: </strong>We compared the impact of a dietary supplement protein complex (Cyplexinol<sup>®</sup>) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.</p><p><strong>Results: </strong>Pain and discomfort scores improved (<i>P</i> ≤ 0.05) for subjects following use of Cyplexinol<sup>®</sup> but not placebo. Improvements were noted for WOMAC pain (<i>P</i> = 0.05), stiffness (<i>P</i> = 0.039), and total pain (<i>P</i> = 0.026), as well as VAS pain (<i>P</i> = 0.015), recreational activity interference (<i>P</i> = 0.023), mood interference (<i>P</i> = 0.012), and total pain (<i>P</i> = 0.024). A trend was noted for WOMAC physical function (<i>P</i> = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol<sup>®</sup> (<i>P</i> = 0.01), with a similar increase noted for placebo (<i>P</i> = 0.022). A near doubling in TGF-β (<i>P</i> = 0.001) was noted for Cyplexinol<sup>®</sup>. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>Cyplexinol<sup>®</sup> can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol<sup>®</sup> does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.</p><p><strong>Relevance for patients: </strong>Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol<sup>®</sup>, as we observed decreased pain and stiffness following treatment.</p>","PeriodicalId":15482,"journal":{"name":"Journal of Clinical and Translational Research","volume":"9 3","pages":"212-221"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/2f/jclintranslres-2023-9-3-212.PMC10339409.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.

Methods: We compared the impact of a dietary supplement protein complex (Cyplexinol®) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.

Results: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol® but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol® (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol®. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05).

Conclusions: Cyplexinol® can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol® does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.

Relevance for patients: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol®, as we observed decreased pain and stiffness following treatment.

Abstract Image

膳食补充剂Cyplexinol®减轻了男性和女性的关节疼痛。
背景和目的:关节痛折磨着全世界数百万的成年人。骨形态发生蛋白复合物对关节疼痛的影响在本研究中进行了评估。方法:我们比较了膳食补充剂蛋白复合物(Cyplexinol®)和安慰剂对18名自我报告关节疼痛的男性和女性(年龄43±10岁)的影响。受试者被随机分配到每一种情况,每天服用两次,持续14天(900毫克/天)。受试者在每个治疗阶段开始和结束时完成问卷调查(例如,安大略省西部和麦克马斯特大学骨关节炎指数(WOMAC)和主观疼痛(使用视觉模拟量表[VAS])。分析血样中骨形态发生蛋白(BMP)、碱性磷酸酶和细胞因子(肿瘤坏死因子[TNF]-α、白细胞介素[IL]-6、IL-10、IL-1β和TGF-β)的含量。还在第1天和第15天采集血液,以确定治疗对这些措施的急性影响。结果:使用Cyplexinol®后,受试者的疼痛和不适评分有改善(P≤0.05),而安慰剂无改善。WOMAC疼痛(P = 0.05)、僵硬(P = 0.039)和总痛(P = 0.026)以及VAS疼痛(P = 0.015)、娱乐活动干扰(P = 0.023)、情绪干扰(P = 0.012)和总痛(P = 0.024)均有改善。WOMAC的生理功能有明显的变化趋势(P = 0.052)。在Cyplexinol®后,BMP5增加了大约50% (P = 0.01),安慰剂组也有类似的增加(P = 0.022)。Cyplexinol®的TGF-β几乎翻倍(P = 0.001)。其他各组间无显著性变化,急性用药后细胞因子无显著性差异(P > 0.05)。结论:Cyplexinol®可减轻中年男性和女性关节疼痛,同时升高BMP5和TGF-β。至少在短的2周补充期内或摄入后2小时内,Cyplexinol®不影响细胞因子。与患者的相关性:患有膝关节和/或髋关节关节疼痛的个体可能受益于日常使用Cyplexinol®,因为我们观察到治疗后疼痛和僵硬减轻。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信